CGT Bispecific T-Cell Engagers: Miltenyi & Thermo Fisher Insights
Our latest product is a groundbreaking advancement in cancer immunotherapy known as CGT Bispecific T-Cell Engagers (BiTEs). Developed by T&L Biotechnology Co., Ltd., these innovative bi-specific Antibodies are designed to redirect T-cell cytotoxicity toward tumor cells, leading to more effective and targeted cancer cell killing, The CGT BiTEs work by simultaneously binding to a specific tumor antigen and to the CD3 receptor on T cells, bringing the two types of cells into close proximity and activating the T cells to attack the tumor cells. This unique approach harnesses the power of the body's own immune system to fight cancer, offering a promising new treatment option for patients
- Minimizing Process Validation Costs In Cgt
- Reducing Waste In Cell Therapy Production
- Low-Cost Analytical Testing For Cgt Products
- Optimizing Supply Chain Logistics For Cgt
- Reducing Transportation Costs For Cell Therapy Products
- Cost-Efficient Car-T Therapy Expansion Platforms
- Affordable Strategies For Reducing Cgt Production Time
- Thermo Fisher Scientific
- Lonza
- Sartorius